For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Constellation Pharmaceuticals, Inc.

Calculating rank

USPTO Granted Patents = 56

% Expired Patents = 1.8

EPO Patents = 43

Forward Citations = 217

Loading Chart...

Loading Chart...

65 inventors (with patents filed for the assignee):

Brian K Albrecht (35 out of 52 patents)

Victor S Gehling (32 out of 32 patents)

Christopher G Nasveschuk (25 out of 66 patents)

4. Jean-Christophe P Harmange (22 out of 57 patents)

5. Alexander M Taylor (18 out of 28 patents)

6. Rishi G Vaswani (17 out of 28 patents)

7. James E Audia (16 out of 99 patents)

8. Steven R Magnuson (15 out of 44 patents)

9. Vickie Hsiao-Wei Tsui (12 out of 26 patents)

10. F Anthony Romero (12 out of 42 patents)

11. Martin Duplessis (12 out of 29 patents)

12. Alexandre Cote (12 out of 12 patents)

13. Alexandre Côté (11 out of 11 patents)

14. Michael Charles Hewitt (11 out of 33 patents)

15. Les A Dakin (11 out of 11 patents)

Core Competencies:

Methyl Modifying Enzymes

LSD1 Inhibitors

Bromodomain Inhibitors

TREX1 Modulators

EZH2 Inhibitors

Myeloproliferative Disorders

Therapeutic Compounds

Crystalline Forms

Histone Demethylase Inhibitors

Pyrazolo Compounds

P300/CBP Inhibitors

Indole Derivatives

56 patents: Sort by Forward Citations

1. 12612390 - Modulators of methyl modifying enzymes, compositions and uses thereof (2026-04-28),

2. 12516040 - Crystalline forms of 7-chloro-2-(4-3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide (2026-01-06),

3. 12172990 - Modulators of TREX1 (2024-12-24),

4. 12070464 - Methods of treating myeloproliferative disorders (2024-08-27),

5. 11919912 - Modulators of methyl modifying enzymes, compositions and uses thereof (2024-03-05),

6. 11547695 - LSD1 inhibitors and medical uses thereof (2023-01-10),

7. 11459315 - Modulators of methyl modifying enzymes, compositions and uses thereof (2022-10-04),

8. 11414384 - P300/CBP hat inhibitors (2022-08-16),

9. 11274095 - Modulators of methyl modifying enzymes, compositions and uses thereof (2022-03-15),

10. 11274090 - P300/CBP HAT inhibitors (2022-03-15),

11. 11247989 - Therapeutic compounds and uses thereof (2022-02-15),

12. 11168070 - Therapeutic compounds and uses thereof (2021-11-09),

13. 11013718 - LSD1 inhibitors and medical uses thereof (2021-05-25),

14. 10918646 - Methods of treating myeloproliferative disorders (2021-02-16),

15. 10696655 - Therapeutic compounds and uses thereof (2020-06-30),

Company Overview

Constellation Pharmaceuticals, Inc., based in Cambridge, MA, specializes in the development of epigenetic modulators aimed at treating various cancers and myeloproliferative disorders. The company focuses on innovative therapeutic compounds, particularly in the realm of methyl modifying enzymes, LSD1 inhibitors, and bromodomain inhibitors. Their research encompasses advanced technologies such as TREX1 modulators and EZH2 inhibitors, positioning them at the forefront of epigenetic research and therapeutic advancements.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

56 Patents

#47 in Cambridge, MA

#363 in Massachusetts

#6,363 in US

#12,755 in the World

Cambridge, MA, United States of America

Constellation Pharmaceuticals, Inc.

Forward Citations = 217

65 inventors:

Brian K Albrecht (35 out of 52 patents)

Victor S Gehling (32 out of 32 patents)

Christopher G Nasveschuk (25 out of 66 patents)

4. Jean-Christophe P Harmange (22 out of 57 patents)

5. Alexander M Taylor (18 out of 28 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Constellation Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/constellation-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…